Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Masaru Fukahori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4916-6381; OpenAlex author ID A5054822214. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers

Papers 16

  1. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  2. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  3. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  4. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  5. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  6. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  7. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  8. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  9. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  10. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Co-author DOI 10.1016/j.jgo.2021.06.011↗
  11. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  12. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  13. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000026052↗
  14. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  15. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗
  16. Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00795-019-00218-5↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 14 shared papers, 2021–2025 · strength 1.85
  2. Kenji Mitsugi · 14 shared papers, 2021–2025 · strength 1.85
  3. Shiho Arima · 14 shared papers, 2021–2025 · strength 1.85
  4. Futa Koga · 14 shared papers, 2021–2025 · strength 1.85
  5. Taro Shibuki · 14 shared papers, 2021–2025 · strength 1.85
  6. Mototsugu Shimokawa · 14 shared papers, 2021–2025 · strength 1.85
  7. Taiga Otsuka · 14 shared papers, 2021–2025 · strength 1.85
  8. Tsuyoshi Shirakawa · 14 shared papers, 2021–2025 · strength 1.85
  9. Azusa Komori · 14 shared papers, 2021–2025 · strength 1.85
  10. Hiroki Taguchi · 14 shared papers, 2021–2025 · strength 1.85
  11. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  12. Yasushi Ide · 13 shared papers, 2021–2025 · strength 1.68
  13. Keisuke Miwa · 5 shared papers, 2021–2025 · strength 0.73
  14. Yoshinobu Okabe · 6 shared papers, 2019–2024 · strength 0.71
  15. Yasunori Kawaguchi · 5 shared papers, 2021–2025 · strength 0.68
  16. Kazuo Nishikawa · 3 shared papers, 2024–2025 · strength 0.47
  17. Shuji Arita · 3 shared papers, 2024–2025 · strength 0.47
  18. Akio Ido · 3 shared papers, 2021–2023 · strength 0.33
  19. Tomoyuki Ushijima · 3 shared papers, 2019–2023 · strength 0.33
  20. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
  21. Takuji Torimura · 2 shared papers, 2019–2021 · strength 0.20
  22. Takahiko Sakaue · 2 shared papers, 2019–2021 · strength 0.20
  23. Tomonori Araki · 1 shared paper, 2025 · strength 0.16
  24. Yoshiki Naito · 1 shared paper, 2021 · strength 0.12
  25. Shinichi Hashimoto · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.